Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Vera Therapeutics (VERA) announced the atacicept Biologics License Application, BLA, for the treatment of adults with immunoglobulin A nephropathy was accepted for Priority Review by the U.S. Food and Drug Administration. The BLA, which was submitted using the Accelerated Approval Program, was assigned a Prescription Drug User Fee Act, PDUFA, target action date of July 7, 2026. If approved, atacicept could offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection.